Botti E - Search Results

1

Allele-specific cytokine responses at the HLA-C locus: implications for psoriasis.

Hundhausen C, Bertoni A, Mak RK, Botti E, Di Meglio P, Clop A, Laggner U, Chimenti S, Hayday AC, Barker JN, Trembath RC, Capon F, Nestle FO. Hundhausen C, et al. Among authors: botti e. J Invest Dermatol. 2012 Mar;132(3 Pt 1):635-41. doi: 10.1038/jid.2011.378. Epub 2011 Nov 24. J Invest Dermatol. 2012. PMID: 22113476 Free PMC article.

2

Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.

Costanzo A, Talamonti M, Botti E, Spallone G, Papoutsaki M, Chimenti S. Costanzo A, et al. Among authors: botti e. Dermatology. 2009;219(1):48-53. doi: 10.1159/000213758. Epub 2009 Apr 16. Dermatology. 2009. PMID: 19372639

3

Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab.

Talamonti M, Botti E, Galluzzo M, Teoli M, Spallone G, Bavetta M, Chimenti S, Costanzo A. Talamonti M, et al. Among authors: botti e. Br J Dermatol. 2013 Aug;169(2):458-63. doi: 10.1111/bjd.12331. Br J Dermatol. 2013. PMID: 23521149

4

Psoriasis, from pathogenesis to therapeutic strategies: IL-21 as a novel potential therapeutic target.

Botti E, Spallone G, Caruso R, Monteleone G, Chimenti S, Costanzo A. Botti E, et al. Curr Pharm Biotechnol. 2012 Aug;13(10):1861-7. doi: 10.2174/138920112802273281. Curr Pharm Biotechnol. 2012. PMID: 22250707 Review.

5

IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.

Galluzzo M, Boca AN, Botti E, Potenza C, Malara G, Malagoli P, Vesa S, Chimenti S, Buzoianu AD, Talamonti M, Costanzo A. Galluzzo M, et al. Among authors: botti e. Dermatology. 2016;232(2):230-6. doi: 10.1159/000441719. Epub 2015 Dec 18. Dermatology. 2016. PMID: 26678060

6

Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy.

Costanzo A, Talamonti M, Spallone G, Botti E, Chimenti MS, Papoutsaki M, Chimenti S. Costanzo A, et al. Among authors: botti e. Dermatology. 2009;218(2):146-50. doi: 10.1159/000168086. Epub 2008 Oct 30. Dermatology. 2009. PMID: 18971577

7

Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations.

Marinari B, Botti E, Bavetta M, Spallone G, Zangrilli A, Talamonti M, Richetta A, Chimenti S, Costanzo A. Marinari B, et al. Among authors: botti e. Drug Dev Res. 2014 Nov;75 Suppl 1:S11-4. doi: 10.1002/ddr.21186. Drug Dev Res. 2014. PMID: 25381966

8

Long-term treatment of plaque psoriasis with efalizumab: an Italian experience.

Costanzo A, Peris K, Talamonti M, Di Cesare A, Fargnoli MC, Botti E, Chimenti S. Costanzo A, et al. Among authors: botti e. Br J Dermatol. 2007 Apr;156 Suppl 2:17-23. doi: 10.1111/j.1365-2133.2007.07765.x. Br J Dermatol. 2007. PMID: 17371319

9

Genetic variations in IL6 and IL12B decreasing the risk for psoriasis.

Boca AN, Talamonti M, Galluzzo M, Botti E, Vesa SC, Chimenti S, Buzoianu AD, Costanzo A. Boca AN, et al. Among authors: botti e. Immunol Lett. 2013 Nov-Dec;156(1-2):127-31. doi: 10.1016/j.imlet.2013.09.028. Epub 2013 Oct 17. Immunol Lett. 2013. PMID: 24140476

10

Patients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspension.

Talamonti M, Teoli M, Botti E, Spallone G, Chimenti S, Costanzo A. Talamonti M, et al. Among authors: botti e. Dermatology. 2011;222(3):250-5. doi: 10.1159/000326111. Epub 2011 Apr 13. Dermatology. 2011. PMID: 21494026

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

79 results

Search Page